论文部分内容阅读
原发性肝细胞癌(下称肝癌)的血清学诊断迄今仍首推甲胎蛋白(AFP),但有其局限性。部分良性肝病患者 AFP 的一过性升高给肝癌诊断增加了困难,另约有20—30％的肝癌患者AFP 呈阴性或浓度升高,故需寻找 AFP 以外的肝癌标记物。本文报告肝癌和良性肝病患者血清 AFP 异质体和 a1—抗胰蛋白酶(AAT)的检测结果,以进一步探讨对肝癌诊断与鉴别诊断的意义。
The serological diagnosis of primary hepatocellular carcinoma (hereinafter referred to as hepatic cancer) has hitherto been the first to determine alpha-fetoprotein (AFP), but has its limitations. The transient increase in AFP in some patients with benign liver disease has increased the difficulty in the diagnosis of liver cancer. In addition, about 20-30% of liver cancer patients have AFP negative or elevated concentrations, so they need to look for markers of liver cancer other than AFP. This paper reports the detection results of serum AFP heteroplasms and a1-antitrypsin (AAT) in patients with hepatocellular carcinoma and benign liver diseases to further explore the significance of diagnosis and differential diagnosis of hepatocellular carcinoma.